[go: up one dir, main page]

WO2007010552A3 - Conjugue d'erythropoietine peg n-terminal - Google Patents

Conjugue d'erythropoietine peg n-terminal Download PDF

Info

Publication number
WO2007010552A3
WO2007010552A3 PCT/IN2006/000103 IN2006000103W WO2007010552A3 WO 2007010552 A3 WO2007010552 A3 WO 2007010552A3 IN 2006000103 W IN2006000103 W IN 2006000103W WO 2007010552 A3 WO2007010552 A3 WO 2007010552A3
Authority
WO
WIPO (PCT)
Prior art keywords
erythropoietin
formula
conjugate
epo
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2006/000103
Other languages
English (en)
Other versions
WO2007010552B1 (fr
WO2007010552A2 (fr
Inventor
Subhash V Kapre
Umesh S Shaligram
Kwang Nho
Gunwon Bae
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Serum Institute of India Pvt Ltd
Sunbio Inc
Original Assignee
Serum Institute of India Pvt Ltd
Sunbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute of India Pvt Ltd, Sunbio Inc filed Critical Serum Institute of India Pvt Ltd
Publication of WO2007010552A2 publication Critical patent/WO2007010552A2/fr
Publication of WO2007010552A3 publication Critical patent/WO2007010552A3/fr
Publication of WO2007010552B1 publication Critical patent/WO2007010552B1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne un conjugué d'érythropoïétine à bioactivité supérieure comprenant une glycoprotéine érythropoïétine avec un groupe a - amino et des dérivés aldéhyde de polyéthylène glycol N-terminal, ladite glycoprotéine érythropoïétine étant sélectionnée dans le groupe formé de l'érythropoïétine humaine et de ses analogues, ledit dérivé aldéhyde de méthoxy polyéthylène glycol étant représenté par la formule PEG-R-CHO, dans laquelle R = un groupe alkyle représenté par la formule -(CH2)n dans laquelle n = 2 à 4. La formule du conjugué de la présente invention est PEG-R-CONH-EPO, formule dans laquelle R = un groupe alkyle représenté par la formule -(CH2)n dans laquelle n = 2 à 4. L'érythropoïétine de la présente invention est une érythropoïétine de recombinaison (rhEPO) produite dans des cellules animales. Ledit conjugué d'érythropoïétine est préparé par expression, fermentation, et purification de la protéine rhEPO dans des cellules animales de recombinaison, et par mise en réaction de l'EPO avec PEG-aldéhyde pour obtenir une EPO à PEG N-terminal par une réaction d'amination réductrice, celle-ci étant ensuite purifiée pour obtenir une EPO à PEG N-terminal pure.
PCT/IN2006/000103 2005-03-17 2006-03-16 Conjugue d'erythropoietine peg n-terminal Ceased WO2007010552A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN291MU2005 2005-03-17
IN291/MUM/2005 2005-03-17

Publications (3)

Publication Number Publication Date
WO2007010552A2 WO2007010552A2 (fr) 2007-01-25
WO2007010552A3 true WO2007010552A3 (fr) 2007-07-12
WO2007010552B1 WO2007010552B1 (fr) 2007-08-23

Family

ID=37528505

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2006/000103 Ceased WO2007010552A2 (fr) 2005-03-17 2006-03-16 Conjugue d'erythropoietine peg n-terminal

Country Status (1)

Country Link
WO (1) WO2007010552A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2653790T3 (es) 2005-08-05 2018-02-08 Araim Pharmaceuticals, Inc. Péptidos protectores de tejido y usos de los mismos
US8101706B2 (en) 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
DK3042922T3 (en) 2008-01-11 2017-10-23 Serina Therapeutics Inc MULTIFUNCTIONAL FORMS OF POLYOXAZOLINE COLPOLYMERS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME
NZ621196A (en) 2008-01-22 2015-08-28 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
CN103118708B (zh) 2010-09-14 2015-08-26 霍夫曼-拉罗奇有限公司 用于纯化聚乙二醇化的促红细胞生成素的方法
CN102453087B (zh) * 2010-10-22 2013-12-25 广东赛保尔生物医药技术有限公司 一种单取代peg-epo的纯化及制备方法
CN102816227A (zh) * 2012-08-30 2012-12-12 深圳赛保尔生物药业有限公司 回收促红细胞生成素的方法
CN109096483B (zh) * 2017-06-28 2020-09-04 北京键凯科技股份有限公司 分枝型多元甘醇环氧衍生物交联透明质酸钠凝胶及其制备和应用
KR102497097B1 (ko) * 2017-12-29 2023-02-06 에프. 호프만-라 로슈 아게 페길화 단백질 조성물의 제공 방법
JP7137625B2 (ja) * 2017-12-29 2022-09-14 エフ．ホフマン－ラ ロシュ アーゲー Ｐｅｇ化タンパク質組成物を提供するための方法
PL3731872T3 (pl) 2017-12-29 2022-03-21 F. Hoffmann-La Roche Ag Sposób dostarczania kompozycji pegylowanego białka
EP3876996A1 (fr) * 2018-11-05 2021-09-15 Bristol-Myers Squibb Company Procédé de purification de protéine pegylée
CN119080909A (zh) * 2024-08-29 2024-12-06 深圳赛保尔生物药业有限公司 负载peg-epo及间充质干细胞的组合物、药物及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011953A1 (fr) * 1994-10-12 1996-04-25 Amgen Inc. Compositions de proteines ayant subi une modification chimique a l'extremite n-terminale et procedes
WO1998005363A2 (fr) * 1996-08-02 1998-02-12 Ortho-Mcneil Pharmaceutical, Inc. Polypeptides possedant un polymere soluble dans l'eau a n-terminal lie par covalence simple
WO2000032772A2 (fr) * 1998-11-30 2000-06-08 Eli Lilly And Company Composes erythropoietiques
WO2002049673A2 (fr) * 2000-12-20 2002-06-27 F. Hoffmann-La Roche Ag Conjugues d'erythropoietine
WO2004009627A1 (fr) * 2002-07-19 2004-01-29 Cangene Corporation Composes erythropoietiques pegyles
US20040116649A1 (en) * 2002-09-09 2004-06-17 Antoni Kozlowski Water-soluble polymer alkanals

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011953A1 (fr) * 1994-10-12 1996-04-25 Amgen Inc. Compositions de proteines ayant subi une modification chimique a l'extremite n-terminale et procedes
WO1998005363A2 (fr) * 1996-08-02 1998-02-12 Ortho-Mcneil Pharmaceutical, Inc. Polypeptides possedant un polymere soluble dans l'eau a n-terminal lie par covalence simple
WO2000032772A2 (fr) * 1998-11-30 2000-06-08 Eli Lilly And Company Composes erythropoietiques
WO2002049673A2 (fr) * 2000-12-20 2002-06-27 F. Hoffmann-La Roche Ag Conjugues d'erythropoietine
WO2004009627A1 (fr) * 2002-07-19 2004-01-29 Cangene Corporation Composes erythropoietiques pegyles
US20040116649A1 (en) * 2002-09-09 2004-06-17 Antoni Kozlowski Water-soluble polymer alkanals

Also Published As

Publication number Publication date
WO2007010552B1 (fr) 2007-08-23
WO2007010552A2 (fr) 2007-01-25

Similar Documents

Publication Publication Date Title
WO2007010552A3 (fr) Conjugue d'erythropoietine peg n-terminal
RU2370276C2 (ru) Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
AU2024227552A1 (en) Conjugates of an IL-2 moiety and a polymer
AU2009227867B2 (en) Reversible pegylated drugs
KR100731826B1 (ko) 유리 시스테인 잔기를 함유하는 단백질의 제조 방법
AU2004238869B2 (en) Novel poly(ethylene glycol) modified compounds and uses thereof
AU2004238870B2 (en) Novel peptides that bind to the erythropoietin receptor
ES2326707T3 (es) Tripeptidos inhibidores de la hepatitis c.
CA2103829C (fr) Conjugues peg-interferon
RU2493168C2 (ru) Пептидное производное - миметик эритропоэтина и его фармацевтические соли, их получение и применение
WO2005065239A3 (fr) Nouvelles proteines recombinees avec thiol libre n-terminal
GEP20084487B (en) Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof
DK1317537T3 (da) Sammensætninger og fremgangsmåder med G-CSF analoger
EP1064951A3 (fr) Dérivés de l' Erythropoietine
WO2006031811A3 (fr) Interferon alpha glycopegyle
IL180727A (en) Antifungal peptides containing motif including arginine and / or lysine
CA2345027A1 (fr) Double polyethyleneglycolation de proteines dirigee sur site pour augmenter la bioactivite et la biocompatibilite
JP2008500275A5 (fr)
MXPA05001716A (es) Conjugados polimericos liberables basados en enlazantes biodegradables alifaticos.
WO2004100997A2 (fr) Nouveau fragment espaceur de composes peptidiques modifies par du poly(ethylene glycol)
RU2006145020A (ru) Полипептиды и конъюгаты интерферона-альфа
JP2005514505A (ja) マルチアーム樹枝状および機能的なｐｅｇの調製法および用途
WO2008052428A1 (fr) Procédé de preparation et conjugué avec molécule médicinale correspondante
DE60313786T2 (de) Poly(ethylen glykol)-konjugate von insulinähnlichem wachstumfaktor bindenden protein-4
KR20100052730A (ko) 생체적합성 고분자와 결합한 신규한 에리스로포이에틴 접합체

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06809896

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6809896

Country of ref document: EP